Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_assertion type Assertion NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_head.
- NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_assertion description "[Whereas BMI1 and RING1 are abundantly present in prostate cancer, EZH2 is expressed at relatively low levels, making it a less obvious target for therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_provenance.
- NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_assertion evidence source_evidence_literature NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_provenance.
- NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_assertion SIO_000772 17134822 NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_provenance.
- NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_assertion wasDerivedFrom befree-20150227 NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_provenance.
- NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_assertion wasGeneratedBy ECO_0000203 NP1016035.RAaTM155JyUyfZ9E5uqUuiR4f9PnY2J5VzRYHO2EZ6ak8130_provenance.